Our study revealed that CRC patients with TET2 mutations exhibited heightened immunogenicity, including elevated TMB, increased neoantigen loads, and a higher MANTIS score compared to the TET2-wild type group, suggesting patients' higher clinical benefit ratio from immunotherapy. The gene discussed is TET2; the disease is colorectal carcinoma.